Skip to main content
Top
Published in: Endocrine Pathology 1/2008

01-04-2008

Transthyretin Amyloid Goiter in a Renal Allograft Recipient

Authors: Vijay K. Vanguri, Vânia Nosé

Published in: Endocrine Pathology | Issue 1/2008

Login to get access

Abstract

Amyloid deposition in the follicular, perifollicular blood vessels, and thyroid stroma can occur in systemic forms of amyloidosis, although diffuse enlargement of the thyroid is generally not present. Marked, widespread enlargement of the thyroid gland with amyloid deposits or amyloid goiter is a rare condition reported in association with primary and secondary amyloidosis but has not been described in association with transthyretin amyloid deposition. Senile transthyretin amyloidosis is primarily associated with amyloid deposits in the heart, while the familial forms of amyloidosis due to transthyretin gene mutations are associated with deposits of amyloid in multiple tissues, classically giving rise to polyneuropathy. In this report, we describe the findings of parathyroid and lymph node amyloid deposits and amyloid goiter with transthyretin reactivity in a recipient of a kidney allograft, reportedly for renal amyloidosis, initially assumed clinically to be due to inflammatory bowel disease-related secondary amyloid deposition. This case underscores the importance of routine immunohistochemical classification of amyloid deposits for accurate diagnosis and to guide clinical management decisions.
Literature
1.
go back to reference Kennedy JS, Thomson JA, Buchanan WM. Amyloid in the thyroid. Q J Med 43:127–43, 1974.PubMed Kennedy JS, Thomson JA, Buchanan WM. Amyloid in the thyroid. Q J Med 43:127–43, 1974.PubMed
2.
go back to reference Hamed G, Heffess CS, Shmookler BM, Wenig BM. Amyloid goiter. A clinicopathologic study of 14 cases and review of the literature. Am J Clin Pathol 104:306–12, 1995.PubMed Hamed G, Heffess CS, Shmookler BM, Wenig BM. Amyloid goiter. A clinicopathologic study of 14 cases and review of the literature. Am J Clin Pathol 104:306–12, 1995.PubMed
3.
go back to reference Altiparmak MR, Pamuk ON, Pamuk GE, Apaydin S, Ataman R, Serdengecti K. Amyloid goitre in familial Mediterranean fever: report on three patients and review of the literature. Clin Rheumatol 21:497–500, 2002.PubMedCrossRef Altiparmak MR, Pamuk ON, Pamuk GE, Apaydin S, Ataman R, Serdengecti K. Amyloid goitre in familial Mediterranean fever: report on three patients and review of the literature. Clin Rheumatol 21:497–500, 2002.PubMedCrossRef
4.
go back to reference Araki S, Yi S. Pathology of familial amyloidotic polyneuropathy with TTR met 30 in Kumamoto, Japan. Neuropathology 20(Suppl):S47–51, 2000.PubMedCrossRef Araki S, Yi S. Pathology of familial amyloidotic polyneuropathy with TTR met 30 in Kumamoto, Japan. Neuropathology 20(Suppl):S47–51, 2000.PubMedCrossRef
5.
go back to reference Sakashita N, Ando Y, Obayashi K, Terazaki H, Yamashita T, Takei M, Kinjo M, Takahashi K. Familial amyloidotic polyneuropathy (ATTR Ser50Ile): the first autopsy case report. Virchows Arch 436:345–50, 2000.PubMedCrossRef Sakashita N, Ando Y, Obayashi K, Terazaki H, Yamashita T, Takei M, Kinjo M, Takahashi K. Familial amyloidotic polyneuropathy (ATTR Ser50Ile): the first autopsy case report. Virchows Arch 436:345–50, 2000.PubMedCrossRef
6.
go back to reference Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63:129–38, 2004.PubMed Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63:129–38, 2004.PubMed
7.
go back to reference Cornwell GG 3rd, Westermark P, Natvig JB, Murdoch W. Senile cardiac amyloid: evidence that fibrils contain a protein immunologically related to prealbumin. Immunology 44:447–52, 1981.PubMed Cornwell GG 3rd, Westermark P, Natvig JB, Murdoch W. Senile cardiac amyloid: evidence that fibrils contain a protein immunologically related to prealbumin. Immunology 44:447–52, 1981.PubMed
8.
go back to reference Westermark P, Bergström J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 10(Suppl 1):48–54, 2003.PubMed Westermark P, Bergström J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 10(Suppl 1):48–54, 2003.PubMed
9.
10.
go back to reference Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 75:4499–503, 1978.PubMedCrossRef Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 75:4499–503, 1978.PubMedCrossRef
11.
go back to reference Pras M, Prelli F, Franklin EC, Frangione B. Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin. Proc Natl Acad Sci USA 80:539–42, 1983.PubMedCrossRef Pras M, Prelli F, Franklin EC, Frangione B. Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin. Proc Natl Acad Sci USA 80:539–42, 1983.PubMedCrossRef
13.
go back to reference Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 62:1057–62, 2005.PubMedCrossRef Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 62:1057–62, 2005.PubMedCrossRef
14.
go back to reference Takahashi K, Yi S, Kimura Y, Araki S. Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study. Hum Pathol 22:519–27, 1991.PubMedCrossRef Takahashi K, Yi S, Kimura Y, Araki S. Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study. Hum Pathol 22:519–27, 1991.PubMedCrossRef
15.
go back to reference Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411–32, 2007.PubMedCrossRef Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411–32, 2007.PubMedCrossRef
16.
17.
go back to reference Kebbel A, Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol 30:673–83, 2006.PubMedCrossRef Kebbel A, Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol 30:673–83, 2006.PubMedCrossRef
18.
go back to reference Purkey HE, Palaninathan SK, Kent KC, Smith C, Safe SH, Sacchettini JC, Kelly JW. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem Biol 11:1719–28, 2004.PubMedCrossRef Purkey HE, Palaninathan SK, Kent KC, Smith C, Safe SH, Sacchettini JC, Kelly JW. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem Biol 11:1719–28, 2004.PubMedCrossRef
19.
go back to reference Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci USA 102:14545–50, 2005.PubMedCrossRef Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci USA 102:14545–50, 2005.PubMedCrossRef
20.
go back to reference Johnson SM, Petrassi HM, Palaninathan SK, Mohamedmohaideen NN, Purkey HE, Nichols C, Chiang KP, Walkup T, Sacchettini JC, Sharpless KB, Kelly JW. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem 48:1576–87, 2005.PubMedCrossRef Johnson SM, Petrassi HM, Palaninathan SK, Mohamedmohaideen NN, Purkey HE, Nichols C, Chiang KP, Walkup T, Sacchettini JC, Sharpless KB, Kelly JW. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem 48:1576–87, 2005.PubMedCrossRef
21.
go back to reference Sato T, Ando Y, Susuki S, Mikami F, Ikemizu S, Nakamura M, Suhr O, Anraku M, Kai T, Suico MA, Shuto T, Mizuguchi M, Yamagata Y, Kai H. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS Lett 580:491–6, 2006.PubMedCrossRef Sato T, Ando Y, Susuki S, Mikami F, Ikemizu S, Nakamura M, Suhr O, Anraku M, Kai T, Suico MA, Shuto T, Mizuguchi M, Yamagata Y, Kai H. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS Lett 580:491–6, 2006.PubMedCrossRef
22.
go back to reference Tagoe CE, Reixach N, Friske L, Mustra D, French D, Gallo G, Buxbaum JN. In vivo stabilization of mutant human transthyretin in transgenic mice. Amyloid 14:227–36, 2007.PubMedCrossRef Tagoe CE, Reixach N, Friske L, Mustra D, French D, Gallo G, Buxbaum JN. In vivo stabilization of mutant human transthyretin in transgenic mice. Amyloid 14:227–36, 2007.PubMedCrossRef
23.
go back to reference Wüthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 37:915–22, 2007.PubMedCrossRef Wüthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 37:915–22, 2007.PubMedCrossRef
24.
go back to reference Goldsmith JD, Lai ML, Daniele GM, Tomaszewski JE, LiVolsi VA. Amyloid goiter: report of two cases and review of the literature. Endocr Pract 6:318–23, 2000.PubMed Goldsmith JD, Lai ML, Daniele GM, Tomaszewski JE, LiVolsi VA. Amyloid goiter: report of two cases and review of the literature. Endocr Pract 6:318–23, 2000.PubMed
25.
go back to reference Kimura H, Yamashita S, Ashizawa K, Yokoyama N, Nagataki S. Thyroid dysfunction in patients with amyloid goitre. Clin Endocrinol (Oxf) 46:769–74, 1997.CrossRef Kimura H, Yamashita S, Ashizawa K, Yokoyama N, Nagataki S. Thyroid dysfunction in patients with amyloid goitre. Clin Endocrinol (Oxf) 46:769–74, 1997.CrossRef
26.
go back to reference Villamil CF, Massimi G, D’Avella J, Cole SR. Amyloid goiter with parathyroid involvement: a case report and review of the literature. Arch Pathol Lab Med 124:281–3, 2000.PubMed Villamil CF, Massimi G, D’Avella J, Cole SR. Amyloid goiter with parathyroid involvement: a case report and review of the literature. Arch Pathol Lab Med 124:281–3, 2000.PubMed
27.
go back to reference Rocken C, Roessner A. An evaluation of antigen retrieval procedures for immunoelectron microscopic classification of amyloid deposits. J Histochem Cytochem 47:1385–94, 1999.PubMed Rocken C, Roessner A. An evaluation of antigen retrieval procedures for immunoelectron microscopic classification of amyloid deposits. J Histochem Cytochem 47:1385–94, 1999.PubMed
28.
go back to reference Ozdemir BH, Uyar P, Ozdemir FN. Diagnosing amyloid goitre with thyroid aspiration biopsy. Cytopathology 17:262–6, 2006.PubMedCrossRef Ozdemir BH, Uyar P, Ozdemir FN. Diagnosing amyloid goitre with thyroid aspiration biopsy. Cytopathology 17:262–6, 2006.PubMedCrossRef
Metadata
Title
Transthyretin Amyloid Goiter in a Renal Allograft Recipient
Authors
Vijay K. Vanguri
Vânia Nosé
Publication date
01-04-2008
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 1/2008
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-008-9020-8

Other articles of this Issue 1/2008

Endocrine Pathology 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine